Co-Diagnostics (CODX) Stock Forecast, Price Target & Predictions
CODX Stock Forecast
Co-Diagnostics stock forecast is as follows: an average price target of $6.00 (represents a 358.02% upside from CODX’s last price of $1.31) and
CODX Price Target
Co-Diagnostics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 14, 2022 | - | H.C. Wainwright | $6.00 | $3.65 | 64.38% | 358.02% |
| Aug 15, 2022 | - | H.C. Wainwright | $9.00 | $4.48 | 100.89% | 587.02% |
| May 16, 2022 | - | H.C. Wainwright | $12.00 | $4.55 | 163.74% | 816.03% |
The latest Co-Diagnostics stock forecast, released on Nov 14, 2022 by H.C. Wainwright company, set a price target of $6.00, which represents a 64.38% increase from the stock price at the time of the forecast ($3.65), and a 358.02% increase from CODX last price ($1.31).
Co-Diagnostics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.31 | $1.31 | $1.31 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Co-Diagnostics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Co-Diagnostics's last price of $1.31. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Co-Diagnostics Financial Forecast
Co-Diagnostics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $3.56M | $2.46M | $197.81K | $601.96K | $1.40M | $5.09M | $5.02M | $22.70M | $20.40M | $30.10M | $27.36M | $20.02M | $27.15M | $21.82M | $24.04M | $1.55M | $108.57K | $41.43K | $61.57K | $3.40K |
| Avg Forecast | $400.00K | $400.00K | $400.00K | $400.00K | $375.00K | $375.00K | $400.00K | $3.10M | $3.63M | $200.00K | $500.00K | $1.10M | $5.50M | $7.48M | $15.34M | $21.17M | $20.93M | $24.32M | $20.77M | $19.89M | $24.99M | $32.80M | $26.45M | $616.33K | $100.00K | $309.00K | $196.00K | $292.00K |
| High Forecast | $400.00K | $400.00K | $400.00K | $400.00K | $375.00K | $375.00K | $400.00K | $3.10M | $3.63M | $200.00K | $500.00K | $1.10M | $5.50M | $7.48M | $15.34M | $21.17M | $20.93M | $24.32M | $20.77M | $19.89M | $24.99M | $32.80M | $26.45M | $616.33K | $100.00K | $309.00K | $196.00K | $292.00K |
| Low Forecast | $400.00K | $400.00K | $400.00K | $400.00K | $375.00K | $375.00K | $400.00K | $3.10M | $3.63M | $200.00K | $500.00K | $1.10M | $5.50M | $7.48M | $15.34M | $21.17M | $20.93M | $24.32M | $20.77M | $19.89M | $24.99M | $32.80M | $26.45M | $616.33K | $100.00K | $309.00K | $196.00K | $292.00K |
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | 0.98% | 12.29% | 0.40% | 0.55% | 0.25% | 0.68% | 0.33% | 1.07% | 0.97% | 1.24% | 1.32% | 1.01% | 1.09% | 0.67% | 0.91% | 2.51% | 1.09% | 0.13% | 0.31% | 0.01% |
Co-Diagnostics's average Quarter revenue forecast for Mar 24 based on 0 analysts is $3.10M, with a low forecast of $3.10M, and a high forecast of $3.10M. CODX's average Quarter revenue forecast represents a -12.80% decrease compared to the company's last Quarter revenue of $3.56M (Dec 23).
Co-Diagnostics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | $-7.80M | $-10.85M | $-11.09M | $4.13M | $-9.11M | $-4.49M | $6.78M | $10.36M | $13.68M | $12.01M | $9.97M | $15.89M | $12.88M | $12.70M | $-1.04M | $-1.71M | $-1.73M | $-1.33M | $-1.25M |
| Avg Forecast | $-82.48K | $-82.48K | $-82.48K | $-82.48K | $-77.33K | $-77.33K | $-82.48K | $-639.24K | $-747.50K | $-41.24K | $-103.10K | $-226.83K | $-1.13M | $-1.54M | $-3.16M | $14.70M | $-4.32M | $-5.01M | $-4.28M | $8.15M | $-5.15M | $-6.76M | $-5.45M | $-1.04M | $-20.62K | $-63.72K | $-40.42K | $-1.09M |
| High Forecast | $-82.48K | $-82.48K | $-82.48K | $-82.48K | $-77.33K | $-77.33K | $-82.48K | $-639.24K | $-747.50K | $-41.24K | $-103.10K | $-226.83K | $-1.13M | $-1.54M | $-3.16M | $17.63M | $-4.32M | $-5.01M | $-4.28M | $9.79M | $-5.15M | $-6.76M | $-5.45M | $-829.50K | $-20.62K | $-63.72K | $-40.42K | $-873.80K |
| Low Forecast | $-82.48K | $-82.48K | $-82.48K | $-82.48K | $-77.33K | $-77.33K | $-82.48K | $-639.24K | $-747.50K | $-41.24K | $-103.10K | $-226.83K | $-1.13M | $-1.54M | $-3.16M | $11.76M | $-4.32M | $-5.01M | $-4.28M | $6.52M | $-5.15M | $-6.76M | $-5.45M | $-1.24M | $-20.62K | $-63.72K | $-40.42K | $-1.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | 189.12% | 105.25% | 48.89% | -3.65% | 5.91% | 1.42% | 0.46% | -2.40% | -2.73% | -2.81% | 1.22% | -3.08% | -1.90% | -2.33% | 1.00% | 83.00% | 27.16% | 32.87% | 1.14% |
0 analysts predict CODX's average Quarter EBITDA for Mar 23 to be $-226.83K, with a high of $-226.83K and a low of $-226.83K. This is -105.49% lower than Co-Diagnostics's previous annual EBITDA (Dec 22) of $4.13M.
Co-Diagnostics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | $-14.68M | $-5.98M | $-8.92M | $-5.76M | $-21.91M | $-1.36M | $-2.69M | $11.71M | $7.50M | $11.48M | $9.79M | $7.90M | $12.81M | $15.73M | $12.64M | $-1.07M | $-1.74M | $-1.75M | $-1.34M | $-1.37M |
| Avg Forecast | $-6.93M | $-8.13M | $-9.94M | $-9.94M | $-9.94M | $-9.94M | $-10.24M | $-6.33M | $-6.02M | $-8.74M | $-7.23M | $-6.78M | $-4.52M | $8.50M | $2.11M | $12.89M | $3.61M | $6.33M | $6.63M | $6.46M | $14.36M | $19.08M | $17.67M | $-1.07M | $-2.71M | $-2.26M | $-2.41M | $-1.20M |
| High Forecast | $-6.93M | $-8.13M | $-9.94M | $-9.94M | $-9.94M | $-9.94M | $-10.24M | $-6.33M | $-6.02M | $-8.74M | $-7.23M | $-6.78M | $-4.52M | $10.21M | $2.11M | $15.46M | $3.61M | $6.33M | $6.63M | $7.76M | $14.36M | $19.08M | $17.67M | $-852.15K | $-2.71M | $-2.26M | $-2.41M | $-957.87K |
| Low Forecast | $-6.93M | $-8.13M | $-9.94M | $-9.94M | $-9.94M | $-9.94M | $-10.24M | $-6.33M | $-6.02M | $-8.74M | $-7.23M | $-6.78M | $-4.52M | $6.80M | $2.11M | $10.31M | $3.61M | $6.33M | $6.63M | $5.17M | $14.36M | $19.08M | $17.67M | $-1.28M | $-2.71M | $-2.26M | $-2.41M | $-1.44M |
| Surprise % | - | - | - | - | - | - | - | - | 2.44% | 0.68% | 1.23% | 0.85% | 4.85% | -0.16% | -1.27% | 0.91% | 2.07% | 1.81% | 1.48% | 1.22% | 0.89% | 0.82% | 0.71% | 1.00% | 0.64% | 0.77% | 0.56% | 1.14% |
Co-Diagnostics's average Quarter net income forecast for Jun 22 is $2.11M, with a range of $2.11M to $2.11M. CODX's average Quarter net income forecast represents a -82.00% decrease compared to the company's last Quarter net income of $11.71M (Mar 22).
Co-Diagnostics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | $5.05M | $5.45M | $4.72M | $6.58M | $5.51M | $3.94M | $5.57M | $5.32M | $7.17M | $8.32M | $4.13M | $5.63M | $3.00M | $2.58M | $1.73M | $1.28M | $1.32M | $1.06M | $896.47K |
| Avg Forecast | $3.49M | $3.49M | $3.49M | $3.49M | $3.27M | $3.27M | $3.49M | $27.03M | $31.60M | $1.74M | $4.36M | $9.59M | $47.95M | $5.32M | $133.74M | $6.13M | $182.48M | $211.99M | $181.03M | $3.38M | $217.88M | $285.90M | $230.58M | $5.37M | $871.78K | $2.69M | $1.71M | $2.55M |
| High Forecast | $3.49M | $3.49M | $3.49M | $3.49M | $3.27M | $3.27M | $3.49M | $27.03M | $31.60M | $1.74M | $4.36M | $9.59M | $47.95M | $6.38M | $133.74M | $7.36M | $182.48M | $211.99M | $181.03M | $4.06M | $217.88M | $285.90M | $230.58M | $5.37M | $871.78K | $2.69M | $1.71M | $2.55M |
| Low Forecast | $3.49M | $3.49M | $3.49M | $3.49M | $3.27M | $3.27M | $3.49M | $27.03M | $31.60M | $1.74M | $4.36M | $9.59M | $47.95M | $4.25M | $133.74M | $4.91M | $182.48M | $211.99M | $181.03M | $2.71M | $217.88M | $285.90M | $230.58M | $5.37M | $871.78K | $2.69M | $1.71M | $2.55M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.90% | 1.25% | 0.49% | 0.14% | 1.04% | 0.03% | 0.91% | 0.03% | 0.03% | 0.05% | 1.22% | 0.03% | 0.01% | 0.01% | 0.32% | 1.47% | 0.49% | 0.62% | 0.35% |
Co-Diagnostics's average Quarter SG&A projection for Dec 23 is $31.60M, based on 1 Wall Street analysts, with a range of $31.60M to $31.60M. The forecast indicates a 525.52% rise compared to CODX last annual SG&A of $5.05M (Sep 23).
Co-Diagnostics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | $-0.50 | $-0.20 | $-0.31 | $-0.20 | $-0.70 | $-0.04 | $-0.08 | $0.35 | $0.26 | $0.40 | $0.34 | $0.28 | $0.46 | $0.56 | $0.46 | $-0.05 | $-0.08 | $-0.10 | $-0.08 | $-0.09 |
| Avg Forecast | $-0.23 | $-0.27 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.34 | $-0.21 | $-0.20 | $-0.29 | $-0.24 | $-0.23 | $-0.15 | $-0.04 | $0.07 | $0.17 | $0.12 | $0.21 | $0.22 | $0.22 | $0.48 | $0.63 | $0.59 | $-0.05 | $-0.09 | $-0.07 | $-0.08 | $-0.08 |
| High Forecast | $-0.23 | $-0.27 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.34 | $-0.21 | $-0.20 | $-0.29 | $-0.24 | $-0.23 | $-0.15 | $-0.04 | $0.07 | $0.17 | $0.12 | $0.21 | $0.22 | $0.22 | $0.48 | $0.63 | $0.59 | $-0.05 | $-0.09 | $-0.07 | $-0.08 | $-0.08 |
| Low Forecast | $-0.23 | $-0.27 | $-0.33 | $-0.33 | $-0.33 | $-0.33 | $-0.34 | $-0.21 | $-0.20 | $-0.29 | $-0.24 | $-0.23 | $-0.15 | $-0.04 | $0.07 | $0.17 | $0.12 | $0.21 | $0.22 | $0.22 | $0.48 | $0.63 | $0.59 | $-0.05 | $-0.09 | $-0.07 | $-0.08 | $-0.08 |
| Surprise % | - | - | - | - | - | - | - | - | 2.50% | 0.69% | 1.29% | 0.89% | 4.67% | 1.02% | -1.18% | 2.02% | 2.17% | 1.90% | 1.55% | 1.27% | 0.96% | 0.88% | 0.78% | 0.94% | 0.84% | 1.33% | 1.00% | 1.13% |
According to 0 Wall Street analysts, Co-Diagnostics's projected average Quarter EPS for Jun 22 is $0.07, with a low estimate of $0.07 and a high estimate of $0.07. This represents a -80.00% decrease compared to CODX previous annual EPS of $0.35 (Mar 22).
Co-Diagnostics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BJDX | Bluejay Diagnostics | $0.15 | $10.00 | 6566.67% | Buy |
| RPID | Rapid Micro Biosystems | $0.84 | $8.00 | 852.38% | Hold |
| CODX | Co-Diagnostics | $1.31 | $6.00 | 358.02% | - |
| INGN | Inogen | $11.33 | $26.00 | 129.48% | Buy |
| CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
| HSCS | Heart Test Laboratories | $3.04 | $3.00 | -1.32% | Buy |
| CLPT | ClearPoint Neuro | $12.59 | $12.00 | -4.69% | Buy |
| OPGN | OpGen | $2.24 | $0.67 | -70.09% | Buy |
CODX Forecast FAQ
Will Co-Diagnostics stock go up soon?
According to Wall Street analysts' prediction for CODX stock, the company can go up by 358.02% (from the last price of $1.31 to the average price target of $6), up by 358.02% based on the highest stock price target, and up by 358.02% based on the lowest stock price target.
Can Co-Diagnostics stock reach $2?
CODX's average twelve months analyst stock price target of $6 supports the claim that Co-Diagnostics can reach $2 in the near future.
What are Co-Diagnostics's analysts' financial forecasts?
Co-Diagnostics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.25M (high $4.25M, low $4.25M), average EBITDA is $-876K (high $-876K, low $-876K), average net income is $-36.451M (high $-36.451M, low $-36.451M), average SG&A $37.05M (high $37.05M, low $37.05M), and average EPS is $-1.21 (high $-1.21, low $-1.21). CODX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.6M (high $1.6M, low $1.6M), average EBITDA is $-330K (high $-330K, low $-330K), average net income is $-34.945M (high $-34.945M, low $-34.945M), average SG&A $13.95M (high $13.95M, low $13.95M), and average EPS is $-1.16 (high $-1.16, low $-1.16).
Did the CODX's actual financial results beat the analysts' financial forecasts?
Based on Co-Diagnostics's last annual report (Dec 2023), the company's revenue was $6.81M, beating the average analysts forecast of $5.42M by 25.57%. Apple's EBITDA was $-36.88M, beating the average prediction of $-1.119M by 3196.78%. The company's net income was $-35.333M, beating the average estimation of $-28.769M by 22.82%. Apple's SG&A was $21.14M, missing the average forecast of $47.29M by -55.30%. Lastly, the company's EPS was $-1.2, beating the average prediction of $-0.955 by 25.65%. In terms of the last quarterly report (Dec 2023), Co-Diagnostics's revenue was $3.56M, missing the average analysts' forecast of $3.62M by -1.93%. The company's EBITDA was $0, missing the average prediction of $-747K by -100.00%. Co-Diagnostics's net income was $-14.676M, beating the average estimation of $-6.025M by 143.60%. The company's SG&A was $0, missing the average forecast of $31.6M by -100.00%. Lastly, the company's EPS was $-0.5, beating the average prediction of $-0.2 by 150.00%